What is Placebo for Navitoclax used for?

Placebo for Navitoclax is indicated for Chronic lymphocytic leukemia (CLL).

Who makes Placebo for Navitoclax?

Placebo for Navitoclax is developed by AbbVie.

What development phase is Placebo for Navitoclax in?

Placebo for Navitoclax is in Phase 3.

What are the side effects of Placebo for Navitoclax?

Common side effects include Thrombocytopenia, Neutropenia, Anemia, Fatigue, Diarrhea.

Last reviewed 2026-04-23 · How we verify

Placebo for Navitoclax

AbbVie · Phase 3 active Small molecule

Navitoclax is an inhibitor of BCL-2 family proteins.

Navitoclax is an inhibitor of BCL-2 family proteins. Used for Chronic lymphocytic leukemia (CLL).

At a glance

Generic name	Placebo for Navitoclax
Sponsor	AbbVie
Target	BCL-2
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

By inhibiting BCL-2 family proteins, navitoclax promotes apoptosis in cancer cells. This leads to a decrease in cancer cell population and potentially slows down disease progression.

Approved indications

Chronic lymphocytic leukemia (CLL)

Common side effects

Thrombocytopenia
Neutropenia
Anemia
Fatigue
Diarrhea

Key clinical trials

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Placebo for Navitoclax CI brief — competitive landscape report
Placebo for Navitoclax updates RSS · CI watch RSS
AbbVie portfolio CI